Published in Clin Cancer Res on February 09, 2010
The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer | NCT01706939
Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol (2012) 3.04
Second primary cancers after an index head and neck cancer: subsite-specific trends in the era of human papillomavirus-associated oropharyngeal cancer. J Clin Oncol (2010) 1.70
Human papillomavirus predicts outcome in oropharyngeal cancer in patients treated primarily with surgery or radiation therapy. Br J Cancer (2010) 1.57
UM-SCC-104: a new human papillomavirus-16-positive cancer stem cell-containing head and neck squamous cell carcinoma cell line. Head Neck (2011) 1.45
Correlation of cellular immunity with human papillomavirus 16 status and outcome in patients with advanced oropharyngeal cancer. Arch Otolaryngol Head Neck Surg (2010) 1.31
Genome-wide methylation and expression differences in HPV(+) and HPV(-) squamous cell carcinoma cell lines are consistent with divergent mechanisms of carcinogenesis. Epigenetics (2011) 1.29
High-risk human papillomavirus detection in oropharyngeal, nasopharyngeal, and oral cavity cancers: comparison of multiple methods. JAMA Otolaryngol Head Neck Surg (2013) 1.19
Characteristics and survival of head and neck cancer by HPV status: a cancer registry-based study. Int J Cancer (2011) 1.14
Human papillomavirus-16 infection in advanced oral cavity cancer patients is related to an increased risk of distant metastases and poor survival. PLoS One (2012) 1.14
Review of the clinical and biologic aspects of human papillomavirus-positive squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys (2014) 0.97
Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer. Oral Oncol (2011) 0.97
Human papillomavirus, smoking, and head and neck cancer. Am J Otolaryngol (2011) 0.95
Long-term prognosis and risk factors among patients with HPV-associated oropharyngeal squamous cell carcinoma. Cancer (2013) 0.94
Human Papillomavirus-associated oropharyngeal cancer: an observational study of diagnosis, prevalence and prognosis in a UK population. BMC Cancer (2013) 0.92
Is radiation dose reduction the right answer for HPV-positive head and neck cancer? Oral Oncol (2013) 0.91
Clinical and molecular characteristics of HNSCC patients with brain metastases: a retrospective study. Eur Arch Otorhinolaryngol (2013) 0.90
Human papillomavirus 16 detected in nasopharyngeal carcinomas in white Americans but not in endemic Southern Chinese patients. Head Neck (2013) 0.90
A patient-centered approach to counseling patients with head and neck cancer undergoing human papillomavirus testing: a clinician's guide. Oncologist (2013) 0.89
Nonendemic HPV-positive nasopharyngeal carcinoma: association with poor prognosis. Int J Radiat Oncol Biol Phys (2014) 0.88
Higher micronutrient intake is associated with human papillomavirus-positive head and neck cancer: a case-only analysis. Nutr Cancer (2011) 0.88
Viral load, gene expression and mapping of viral integration sites in HPV16-associated HNSCC cell lines. Int J Cancer (2014) 0.88
Low risk of second primary malignancies among never smokers with human papillomavirus-associated index oropharyngeal cancers. Head Neck (2012) 0.87
Recently identified biomarkers that promote lymph node metastasis in head and neck squamous cell carcinoma. Cancers (Basel) (2011) 0.86
Comprehensive analysis of DNA methylation in head and neck squamous cell carcinoma indicates differences by survival and clinicopathologic characteristics. PLoS One (2013) 0.86
NDN and CD1A are novel prognostic methylation markers in patients with head and neck squamous carcinomas. BMC Cancer (2015) 0.86
Management of oropharyngeal cancer: a cross-sectional review of institutional practice at a large Canadian referral centre. J Otolaryngol Head Neck Surg (2014) 0.86
Prevalence and predictive role of p16 and epidermal growth factor receptor in surgically treated oropharyngeal and oral cavity cancer. Head Neck (2012) 0.85
Human papillomavirus and oropharyngeal squamous cell carcinoma: what the clinician should know. Eur Arch Otorhinolaryngol (2012) 0.85
HPV in oropharyngeal cancer: the basics to know in clinical practice. Acta Otorhinolaryngol Ital (2014) 0.85
Oral epithelial stem cells - implications in normal development and cancer metastasis. Exp Cell Res (2014) 0.84
High XRCC1 protein expression is associated with poorer survival in patients with head and neck squamous cell carcinoma. Clin Cancer Res (2011) 0.84
Geriatric oncology: comparing health related quality of life in head and neck cancer patients. Head Neck Oncol (2011) 0.84
Discrimination of 'driver' and 'passenger' HPV in tonsillar carcinomas by the polymerase chain reaction, chromogenic in situ hybridization, and p16(INK4a) immunohistochemistry. Head Neck Pathol (2011) 0.84
HPV-Associated Head and Neck Cancer: Unique Features of Epidemiology and Clinical Management. Annu Rev Med (2015) 0.84
Viable tumor in postchemoradiation neck dissection specimens as an indicator of poor outcome. Head Neck (2010) 0.83
Opportunities and challenges facing biomarker development for personalized head and neck cancer treatment. Head Neck (2012) 0.83
Definitive radiation therapy without chemotherapy for human papillomavirus-positive head and neck cancer. Head Neck (2013) 0.83
HPV Prevalence and Prognostic Value in a Prospective Cohort of 255 Patients with Locally Advanced HNSCC: A Single-Centre Experience. Int J Otolaryngol (2013) 0.83
Proton pump inhibitors and histamine 2 blockers are associated with improved overall survival in patients with head and neck squamous carcinoma. Cancer Prev Res (Phila) (2014) 0.82
Human papillomavirus-related oropharyngeal cancer: HPV and p16 status in the recurrent versus parent tumor. Head Neck (2014) 0.82
Pretreatment dietary intake is associated with tumor suppressor DNA methylation in head and neck squamous cell carcinomas. Epigenetics (2012) 0.82
Evidence that alpha-9 human papillomavirus infections are a major etiologic factor for oropharyngeal carcinoma in black South Africans. Head Neck Pathol (2013) 0.80
Matted nodes: High distant-metastasis risk and a potential indication for intensification of systemic therapy in human papillomavirus-related oropharyngeal cancer. Head Neck (2015) 0.80
Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds. Semin Cancer Biol (2015) 0.79
Impact of retropharyngeal adenopathy on distant control and survival in HPV-related oropharyngeal cancer treated with chemoradiotherapy. Radiother Oncol (2015) 0.79
Genetic determinants in head and neck squamous cell carcinoma and their influence on global personalized medicine. Genes Cancer (2016) 0.79
Management of locally advanced HPV-related oropharyngeal squamous cell carcinoma: where are we? Eur Arch Otorhinolaryngol (2015) 0.78
Nuances in the changing epidemiology of head and neck cancer. Oncology (Williston Park) (2010) 0.77
The impact of low-dose carcinogens and environmental disruptors on tissue invasion and metastasis. Carcinogenesis (2015) 0.77
Cigarette use, comorbidities, and prognosis in a prospective head and neck squamous cell carcinoma population. Head Neck (2016) 0.77
Human papilloma virus and survival of oropharyngeal cancer patients treated with surgery and adjuvant radiotherapy. Eur Arch Otorhinolaryngol (2014) 0.77
Stability of methylation markers in head and neck squamous cell carcinoma. Head Neck (2015) 0.77
The rationale for HPV-related oropharyngeal cancer de-escalation treatment strategies. Contemp Oncol (Pozn) (2015) 0.76
Surgically treated oropharyngeal cancer: risk factors and tumor characteristics. J Cancer Res Clin Oncol (2014) 0.76
No Ifs, No Butts: Compliance with Smoking Cessation in Secondary Care Guidance (NICE PH48) by Providers of Cancer Therapies (Radiotherapy and Chemotherapy) in the UK. Int J Environ Res Public Health (2016) 0.75
Genomic Integration of High-Risk HPV Alters Gene Expression in Oropharyngeal Squamous Cell Carcinoma. Mol Cancer Res (2016) 0.75
Subtypes of HPV-Positive Head and Neck Cancers Are Associated with HPV Characteristics, Copy Number Alterations, PIK3CA Mutation, and Pathway Signatures. Clin Cancer Res (2016) 0.75
Classical risk factors, but not HPV status, predict survival after chemoradiotherapy in advanced head and neck cancer patients. J Cancer Res Clin Oncol (2016) 0.75
Stereotactic body radiotherapy for recurrent oropharyngeal cancer - influence of HPV status and smoking history. Oral Oncol (2014) 0.75
Human papilloma virus prevalence in a multiethnic screening population. Otolaryngol Head Neck Surg (2013) 0.75
Integration of high-risk human papillomavirus into cellular cancer-related genes in head and neck cancer cell lines. Head Neck (2017) 0.75
Human Papillomavirus 16 Infection and TP53 Mutation: Two Distinct Pathogeneses for Oropharyngeal Squamous Cell Carcinoma in an Eastern Chinese Population. PLoS One (2016) 0.75
Human papillomavirus infection in 674 Chinese patients with laryngeal squamous cell carcinoma. PLoS One (2014) 0.75
Site disparities in apoptotic variants as predictors of risk for second primary malignancy in patients with squamous cell carcinoma of the head and neck. BMC Cancer (2016) 0.75
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med (2007) 16.39
Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst (2000) 14.43
Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst (2008) 12.77
Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev (2005) 9.47
Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst (2008) 8.70
Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer (1999) 8.61
Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol (2008) 7.97
High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol (2006) 5.86
EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol (2008) 5.46
Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers? Cancer (2007) 4.20
Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer (2007) 3.98
Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20-44 years. Cancer (2005) 3.79
Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer (2001) 3.61
Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol (2008) 3.55
Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. Int J Radiat Oncol Biol Phys (1995) 3.32
Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol (2006) 2.91
Lack of association of alcohol and tobacco with HPV16-associated head and neck cancer. J Natl Cancer Inst (2007) 2.68
Marked differences in survival rate between smokers and nonsmokers with HPV 16-associated tonsillar carcinomas. Int J Cancer (2008) 2.62
Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer (2001) 2.35
The epidemiology and risk factors of head and neck cancer: a focus on human papillomavirus. J Dent Res (2007) 2.24
HPV integration begins in the tonsillar crypt and leads to the alteration of p16, EGFR and c-myc during tumor formation. Int J Cancer (2007) 1.80
Sensitive detection of human papillomavirus in cervical, head/neck, and schistosomiasis-associated bladder malignancies. Proc Natl Acad Sci U S A (2005) 1.74
Human papillomavirus positivity predicts favourable outcome for squamous carcinoma of the tonsil. Int J Cancer (2003) 1.68
Human papillomavirus and p53 mutational status as prognostic factors in head and neck carcinoma. Head Neck (2002) 1.32
Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems. Int J Radiat Oncol Biol Phys (2003) 1.31
Chapter 7: Human papillomavirus and cancer of the upper aerodigestive tract. J Natl Cancer Inst Monogr (2003) 1.05
Concomitant b.i.d. radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in unresectable squamous-cell carcinoma of the pharynx: clinical and pharmacological data of a French multicenter phase II study. Int J Radiat Oncol Biol Phys (1998) 0.87
Tumor response, mucosal reactions and late effects after conventional and hyperfractionated radiotherapy. Radiother Oncol (1998) 0.86
Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med (1991) 6.39
EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol (2008) 5.46
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med (2015) 5.39
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol (2008) 5.04
Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys (2010) 4.33
CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC,RTOG consensus guidelines. Radiother Oncol (2003) 3.78
Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol (2008) 3.55
Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell (2011) 3.53
Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis. Int J Radiat Oncol Biol Phys (2006) 3.40
Objective assessment of swallowing dysfunction and aspiration after radiation concurrent with chemotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys (2002) 3.39
The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet (2013) 3.39
Neck dissection classification update: revisions proposed by the American Head and Neck Society and the American Academy of Otolaryngology-Head and Neck Surgery. Arch Otolaryngol Head Neck Surg (2002) 3.37
Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: early dose-effect relationships for the swallowing structures. Int J Radiat Oncol Biol Phys (2007) 3.34
Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol (2009) 3.21
Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov (2013) 3.13
Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer (2008) 2.98
Therapeutic targeting of SPINK1-positive prostate cancer. Sci Transl Med (2011) 2.83
Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head Neck (2010) 2.76
American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol (2006) 2.68
Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm. J Clin Oncol (2005) 2.65
Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol (2006) 2.61
Targeted gold nanoparticles enable molecular CT imaging of cancer. Nano Lett (2008) 2.55
Genotyping of 73 UM-SCC head and neck squamous cell carcinoma cell lines. Head Neck (2010) 2.51
Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci U S A (2013) 2.49
Head and neck squamous cell carcinoma cell lines: established models and rationale for selection. Head Neck (2007) 2.49
Radiotherapy dose-volume effects on salivary gland function. Int J Radiat Oncol Biol Phys (2010) 2.48
Lack of osteoradionecrosis of the mandible after intensity-modulated radiotherapy for head and neck cancer: likely contributions of both dental care and improved dose distributions. Int J Radiat Oncol Biol Phys (2007) 2.48
Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. Cancer Cell (2005) 2.47
Prevention and treatment of dysphagia and aspiration after chemoradiation for head and neck cancer. J Clin Oncol (2006) 2.45
Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results. J Clin Oncol (2010) 2.41
Pretreatment health behaviors predict survival among patients with head and neck squamous cell carcinoma. J Clin Oncol (2009) 2.38
Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clin Cancer Res (2011) 2.31
Transoral robotic surgery for oropharyngeal cancer: long-term quality of life and functional outcomes. JAMA Otolaryngol Head Neck Surg (2013) 2.31
Vascularized tissue to reduce fistula following salvage total laryngectomy: a systematic review. Laryngoscope (2014) 2.21
Parotid glands dose-effect relationships based on their actually delivered doses: implications for adaptive replanning in radiation therapy of head-and-neck cancer. Int J Radiat Oncol Biol Phys (2013) 2.19
A feasibility study of parametric response map analysis of diffusion-weighted magnetic resonance imaging scans of head and neck cancer patients for providing early detection of therapeutic efficacy. Transl Oncol (2009) 2.10
IL-6 promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway. Mol Cancer Res (2011) 2.08
Recurrences near base of skull after IMRT for head-and-neck cancer: implications for target delineation in high neck and for parotid gland sparing. Int J Radiat Oncol Biol Phys (2004) 2.00
Dose-effect relationships for the submandibular salivary glands and implications for their sparing by intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys (2008) 1.99
A hormone-DNA repair circuit governs the response to genotoxic insult. Cancer Discov (2013) 1.97
Lean management in academic surgery. J Am Coll Surg (2012) 1.97
Contemporary management of lymph node metastases from an unknown primary to the neck: I. A review of diagnostic approaches. Head Neck (2011) 1.97
Proposal for the delineation of the nodal CTV in the node-positive and the post-operative neck. Radiother Oncol (2006) 1.95
Intensity-modulated radiation therapy for head and neck carcinoma. Oncologist (2007) 1.94
Neuroendocrine neoplasms of the larynx: an overview. Head Neck (2009) 1.92
Clinical predictors of quality of life in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg (2004) 1.91
Design and implementation of an anthropomorphic quality assurance phantom for intensity-modulated radiation therapy for the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys (2005) 1.90
A placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment. Am J Psychiatry (2002) 1.89
Endothelial cell-initiated signaling promotes the survival and self-renewal of cancer stem cells. Cancer Res (2010) 1.88
A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Cancer Res (2006) 1.85
Merkel cell carcinoma: critical review with guidelines for multidisciplinary management. Cancer (2007) 1.83